Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

November 10, 2015

"We also expect to move additional network-targeted agents from our proprietary portfolio into clinical studies in the near future," Mr. Passeri continued. "In 2011, we expect to select at least one new development candidate, and are continuing studies in compounds targeting HDAC and PI3 kinase as well as in CU-201 and other molecules from this class. We also are currently exploring potential development collaborations around CU-201 and related compounds."

Curis' discovery and development efforts are focused on building a portfolio of small molecule network-targeted inhibitors against a wide range of cancer types. Compounds within each of Curis' research and development programs are designed to inhibit one or more validated cancer targets, including EGFR, Her2, PI3K, Abl, SRC family kinases and others, as well as the inhibition of histone deacetylase, or HDAC, a validated non-kinase cancer target. Each target combination is chosen for its potential of mechanistic synergy, an approach intended to disrupt cancer resistance networks and provide a more durable response for the cancer patient. This potential breakthrough approach in cancer therapy differentiates Curis from other cancer-focused companies.

SOURCE Curis, Inc.